Publications

  1. Issa N, Chedid M, Irazabal MV, Dean PG, Chebib FT. Twenty-Year Survival of Kidney Transplant From a Deceased Donor With Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2021 Aug; 6 (8):2240-2242 Epub 2021 June 10
    View PubMed
  2. Arroyo J, Escobar-Zarate D, Wells HH, Constans MM, Thao K, Smith JM, Sieben CJ, Martell MR, Kline TL, Irazabal MV, Torres VE, Hopp K, Harris PC. The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1(RC/RC) mouse model of autosomal dominant polycystic kidney disease. Kidney Int. 2021 Jun; 99 (6):1392-1407 Epub 2021 Mar 09
    View PubMed
  3. Shukoor SS, Vaughan LE, Edwards ME, Lavu S, Kline TL, Senum SR, Mkhaimer Y, Zaatari G, Irazabal MV, Neal R, Hogan MC, Zoghby ZM, Harris PC, Torres VE, Chebib FT. Characteristics of Patients with End-Stage Kidney Disease in ADPKD. Kidney Int Rep. 2021 Mar; 6 (3):755-767 Epub 2020 Dec 31
    View PubMed
  4. Casal Moura M, Irazabal MV, Eirin A, Zand L, Sethi S, Borah BJ, Winters JL, Moriarty JP, Cartin-Ceba R, Berti A, Baqir M, Thompson GE, Makol A, Warrington KJ, Thao V, Specks U, Fervenza FC. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease. J Am Soc Nephrol. 2020 Nov; 31 (11):2688-2704 Epub 2020 Aug 21
    View PubMed
  5. Bae KT, Shi T, Tao C, Yu ASL, Torres VE, Perrone RD, Chapman AB, Brosnahan G, Steinman TI, Braun WE, Srivastava A, Irazabal MV, Abebe KZ, Harris PC, Landsittel DP, HALT PKD Consortium. Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2020 Jul; 31 (7):1640-1651 Epub 2020 June 02
    View PubMed
  6. Irazabal MV, Torres VE. Reactive Oxygen Species and Redox Signaling in Chronic Kidney Disease. Cells. 2020 May 28; 9 (6)
    View PubMed
  7. Kahveci AS, Barnatan TT, Kahveci A, Adrian AE, Arroyo J, Eirin A, Harris PC, Lerman A, Lerman LO, Torres VE, Irazabal MV. Oxidative Stress and Mitochondrial Abnormalities Contribute to Decreased Endothelial Nitric Oxide Synthase Expression and Renal Disease Progression in Early Experimental Polycystic Kidney Disease. Int J Mol Sci. 2020 Mar 14; 21 (6)
    View PubMed
  8. Sanchis IM, Shukoor S, Irazabal MV, Madsen CD, Chebib FT, Hogan MC, El-Zoghby Z, Harris PC, Huston J, Brown RD, Torres VE. Presymptomatic Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2019 Aug 7; 14 (8):1151-1160 Epub 2019 July 30
    View PubMed
  9. Fervenza FC, Gavrilova RH, Nasr SH, Irazabal MV, Nath KA. CKD Due to a Novel Mitochondrial DNA Mutation: A Case Report. Am J Kidney Dis. 2019 Feb; 73 (2):273-277 Epub 2018 Oct 08
    View PubMed
  10. Maksimovic I, Zhang S, Vuckovic I, Irazabal MV. Kidney harvesting and metabolite extraction for metabolomics studies in rodents. Methods Cell Biol. 2019; 154:15-29 Epub 2019 July 26
    View PubMed
  11. Kline TL, Sussman CR, Irazabal MV, Mishra PK, Pearson EA, Torres VE, Macura SI. Three-dimensional NMR microscopy of zebrafish specimens. NMR Biomed. 2019 Jan; 32 (1):e4031 Epub 2018 Nov 15
    View PubMed
  12. Irazabal MV , Arroyo J , Vuckovic I , Zhang S , Dzeja P , Macura S , Harris PC , Torres VE . Mitochondrial Metabolic Dysregulation and Structural Abnormalities in a Rat Model of Polycystic Kidney Disease FASB Journal. 03 October 2018; 31(S1):1032.3-1032.3.
  13. Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, Senum SR, Hogan MC, El-Zoghby ZM, Kline TL, Harris PC, Czerwiec FS, Torres VE. Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2018 Aug 7; 13 (8):1153-1161 Epub 2018 July 19
    View PubMed
  14. Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol Dial Transplant. 2018 Apr 1; 33 (4):645-652
    View PubMed
  15. Kline TL, Edwards ME, Garg I, Irazabal MV, Korfiatis P, Harris PC, King BF, Torres VE, Venkatesh SK, Erickson BJ. Quantitative MRI of kidneys in renal disease. Abdom Radiol (NY). 2018 Mar; 43 (3):629-638
    View PubMed
  16. Irazabal MV, Abebe KZ, Bae KT, Perrone RD, Chapman AB, Schrier RW, Yu AS, Braun WE, Steinman TI, Harris PC, Flessner MF, Torres VE, HALT Investigators. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant. 2017 Nov 1; 32 (11):1857-1865
    View PubMed
  17. Ye H, Wang X, Constans MM, Sussman CR, Chebib FT, Irazabal MV, Young WF Jr, Harris PC, Kirschner LS, Torres VE. The regulatory 1alpha subunit of protein kinase A modulates renal cystogenesis. Am J Physiol Renal Physiol. 2017 Sep 1; 313 (3):F677-F686 Epub 2017 June 14
    View PubMed
  18. Chebib FT, Hogan MC, El-Zoghby ZM, Irazabal MV, Senum SR, Heyer CM, Madsen CD, Cornec-Le Gall E, Behfar A, Harris PC, Torres VE. Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies. Kidney Int Rep. 2017 Sep; 2 (5):913-923 Epub 2017 June 06
    View PubMed
  19. Shen C, Landsittel D, Irazabal MV, Yu AS, Chapman AB, Mrug M, Grantham JJ, Bae KT, Bennett WM, Flessner MF, Torres VE, CRISP Investigators. Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease. Am J Kidney Dis 2017 Mar; 69 (3):482-484 Epub 2016 Dec 24
    View PubMed
  20. Wang X, Yamada S, LaRiviere WB, Ye H, Bakeberg JL, Irazabal MV, Chebib FT, van Deursen J, Harris PC, Sussman CR, Behfar A, Ward CJ, Torres VE. Generation and phenotypic characterization of Pde1a mutant mice. PLoS One. 2017; 12 (7):e0181087 Epub 2017 July 27
    View PubMed
  21. Irazabal MV, Blais JD, Perrone RD, Gansevoort RT, Chapman AB, Devuyst O, Higashihara E, Harris PC, Zhou W, Ouyang J, Czerwiec FS, Torres VE. Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial. Kidney Int Rep. 2016 Nov; 1 (4):213-220 Epub 2016 Aug 06
    View PubMed
  22. Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC, HALT PKD and CRISP Investigators. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016 Sep; 27 (9):2872-84 Epub 2016 Jan 28
    View PubMed
  23. Chebib FT, Harmon A, Irazabal Mira MV, Jung YS, Edwards ME, Hogan MC, Kamath PS, Torres VE, Nagorney DM. Outcomes and Durability of Hepatic Reduction after Combined Partial Hepatectomy and Cyst Fenestration for Massive Polycystic Liver Disease. J Am Coll Surg. 2016 Jul; 223 (1):118-126.e1 Epub 2016 Jan 14
    View PubMed
  24. Chebib FT, Jung Y, Heyer CM, Irazabal MV, Hogan MC, Harris PC, Torres VE, El-Zoghby ZM. Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2016 Jun; 31 (6):952-60 Epub 2016 Feb 29
    View PubMed
  25. Kim B, King BF Jr, Vrtiska TJ, Irazabal MV, Torres VE, Harris PC. Inherited renal cystic diseases. Abdom Radiol (NY). 2016 Jun; 41 (6):1035-51
    View PubMed
  26. Ye H, Wang X, Sussman CR, Hopp K, Irazabal MV, Bakeberg JL, LaRiviere WB, Manganiello VC, Vorhees CV, Zhao H, Harris PC, van Deursen J, Ward CJ, Torres VE. Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 Subfamilies. J Am Soc Nephrol. 2016 May; 27 (5):1312-20 Epub 2015 Sept 15
    View PubMed
  27. Kline TL, Irazabal MV, Ebrahimi B, Hopp K, Udoji KN, Warner JD, Korfiatis P, Mishra PK, Macura SI, Venkatesh SK, Lerman LO, Harris PC, Torres VE, King BF, Erickson BJ. Utilizing magnetization transfer imaging to investigate tissue remodeling in a murine model of autosomal dominant polycystic kidney disease. Magn Reson Med. 2016 Apr; 75 (4):1466-73 Epub 2015 May 13
    View PubMed
  28. Kline TL, Korfiatis P, Edwards ME, Warner JD, Irazabal MV, King BF, Torres VE, Erickson BJ. Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression. Nephrol Dial Transplant. 2016 Feb; 31 (2):241-8 Epub 2015 Aug 31
    View PubMed
  29. Jung Y, Irazabal MV, Chebib FT, Harris PC, Dean PG, Prieto M, Cosio FG, El-Zoghby ZM, Torres VE. Volume regression of native polycystic kidneys after renal transplantation. Nephrol Dial Transplant. 2016 Jan; 31 (1):73-9 Epub 2015 June 04
    View PubMed
  30. Chebib FT, Prieto M, Jung Y, Irazabal MV, Kremers WK, Dean PG, Rea DJ, Cosio FG, Torres VE, El-Zoghby ZM. Native Nephrectomy in Renal Transplant Recipients with Autosomal Dominant Polycystic Kidney Disease. Transplant Direct. 2015 Nov 1; 1 (10):e43 Epub 2015 Nov 18
    View PubMed
  31. Hogan MC, Masyuk T, Bergstralh E, Li B, Kremers WK, Vaughan LE, Ihrke A, Severson AL, Irazabal MV, Glockner J, LaRusso NF, Torres VE. Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease. Mayo Clin Proc. 2015 Aug; 90 (8):1030-7 Epub 2015 July 09
    View PubMed
  32. Hogan MC, Bakeberg JL, Gainullin VG, Irazabal MV, Harmon AJ, Lieske JC, Charlesworth MC, Johnson KL, Madden BJ, Zenka RM, McCormick DJ, Sundsbak JL, Heyer CM, Torres VE, Harris PC, Ward CJ. Identification of Biomarkers for PKD1 Using Urinary Exosomes. J Am Soc Nephrol. 2015 Jul; 26 (7):1661-70 Epub 2014 Dec 04
    View PubMed
  33. Irazabal MV, Mishra PK, Torres VE, Macura SI. Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring. J Vis Exp. 2015 Jun 23; (100):e52757 Epub 2015 June 23
    View PubMed
  34. Eirin A, Irazabal MV, Fervenza FC, Sethi S. Histiocytic glomerulopathy associated with macrophage activation syndrome. Clin Kidney J. 2015 Apr; 8 (2):157-60 Epub 2015 Feb 17
    View PubMed
  35. LaRiviere WB, Irazabal MV, Torres VE. Novel therapeutic approaches to autosomal dominant polycystic kidney disease. Transl Res. 2015 Apr; 165 (4):488-98 Epub 2014 Nov 13
    View PubMed
  36. Hopp K, Wang X, Ye H, Irazabal MV, Harris PC, Torres VE. Effects of hydration in rats and mice with polycystic kidney disease. Am J Physiol Renal Physiol. 2015 Feb 1; 308 (3):F261-6 Epub 2014 Dec 10
    View PubMed
  37. Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE, CRISP Investigators. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015 Jan; 26 (1):160-72 Epub 2014 June 05
    View PubMed
  38. Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC, Mentor Consortium group. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). Nephron. 2015; 130 (3):159-68 Epub 2015 June 12
    View PubMed
  39. Warner JD, Irazabal MV, Krishnamurthi G, King BF, Torres VE, Erickson BJ. Supervised segmentation of polycystic kidneys: a new application for stereology data. J Digit Imaging. 2014 Aug; 27 (4):514-9
    View PubMed
  40. Warner JD, Irazabal MV, Torres VE, King BF, Erickson BJ. Regional cyst concentration as a prognostic biomarker for polycystic kidney disease. Progress in Biomedical Optics and Imaging - Proceedings of SPIE. 2014; 9038:903804.
  41. Irazabal MV, Torres VE. Experimental therapies and ongoing clinical trials to slow down progression of ADPKD. Curr Hypertens Rev. 2013 Feb; 9 (1):44-59
    View PubMed
  42. Irazabal MV, Eirin A, Lieske J, Beck LH, Sethi S, Borland TM, Dillon JJ, Nachman PH, Nasr SH, Cornell LD, Leung N, Cattran DC, Fervenza FC. Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Nephrol Dial Transplant. 2013 Jan; 28 (1):137-46 Epub 2012 Sept 17
    View PubMed
  43. Leung N, Gertz M, Kyle RA, Fervenza FC, Irazabal MV, Eirin A, Kumar S, Cha SS, Rajkumar SV, Lacy MQ, Zeldenrust SR, Buadi FK, Hayman SR, Nasr SH, Sethi S, Ramirez-Alvarado M, Witzig TE, Herrmann SM, Dispenzieri A. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clin J Am Soc Nephrol. 2012 Dec; 7 (12):1964-8 Epub 2012 Sept 27
    View PubMed
  44. Hogan MC, Masyuk TV, Page L, Holmes DR 3rd, Li X, Bergstralh EJ, Irazabal MV, Kim B, King BF, Glockner JF, Larusso NF, Torres VE. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant. 2012 Sep; 27 (9):3532-9 Epub 2012 July 06
    View PubMed
  45. Eirin A, Irazabal MV, Gertz MA, Dispenzieri A, Lacy MQ, Kumar S, Sethi S, Nasr SH, Cornell LD, Fidler ME, Fervenza FC, Leung N. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrol Dial Transplant. 2012 Mar; 27(3):1097-101. Epub 2011 Nov 07.
    View PubMed
  46. Irazabal MV, Eirin A, Gertz MA, Dispenzieri A, Kumar S, Buadi FK, Lacy MQ, Hayman SR, Dingli D, Hogan WJ, Gastineau DA, Glavey SV, Amer H, Leung N. Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis. Am J Hematol. 2012 Jan; 87(1):51-4. Epub 2011 Nov 11.
    View PubMed
  47. Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2011 Aug; 80 (3):295-301 Epub 2011 May 04
    View PubMed
  48. Geetha D, Eirin A, True K, Valentina Irazabal M, Specks U, Seo P, Nachman P, Fervenza FC. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a multicenter experience. Transplantation. 2011 Jun 27; 91(12):1370-5.
    View PubMed
  49. Irazabal MV, Huston J 3rd, Kubly V, Rossetti S, Sundsbak JL, Hogan MC, Harris PC, Brown RD Jr, Torres VE. Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011 Jun; 6 (6):1274-85 Epub 2011 May 05
    View PubMed
  50. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC, Mayo Nephrology Collaborative Group. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol. 2010 Dec; 5 (12):2188-98 Epub 2010 Aug 12
    View PubMed
  51. Silva F, Specks U, Sethi S, Irazabal MV, Fervenza FC. Successful pregnancy and delivery of a healthy newborn despite transplacental transfer of antimyeloperoxidase antibodies from a mother with microscopic polyangiitis. Am J Kidney Dis. 2009 Sep; 54(3):542-5. Epub 2009 Apr 23.
    View PubMed
  52. Leung N, Eirin A, Irazabal MV, Maddox DE, Gunderson HD, Fervenza FC, Garovic VD. Acute kidney injury in patients with inactive cytochrome P450 polymorphisms. Ren Fail. 2009; 31: (8)749-52.
    View PubMed